iOnctura
Switzerland - GenevaBiotechnology
Focus: iOnctura is a Swiss immuno-oncology biotech focused on targeted cancer therapies, operating at early stage with a lean team of 1–50 employees. The company is advancing a pipeline centered on roginolisib and companion assets across multiple oncology indications.
Profile data last refreshed 23h ago · AI intelligence enriched 1w ago
Funding Stage
SERIES A
Employees
1-50
Open Jobs
0
About iOnctura
AI assessmentNot HiringNo open roles listed right now. Follow iOnctura to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from iOnctura's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
7 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
IOA-289
HealthyClinical Trials (1)
NCT05027568A Study to Assess an ATX Inhibitor (IOA-289) in Healthy Volunteers
Phase 1Help build intelligence for iOnctura
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.